SCHEMBL23925907

SCHEMBL23925907

COC(=O)c1nsnc1C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.48
THRB P10828 1/20 0.39
RAB9A P51151 1/20 0.39
KDM4C Q9H3R0 1/20 0.36
KDM4E B2RXH2 11/20 0.36
STAT3 P40763 1/20 0.36
HIF1A Q16665 1/20 0.36
ALDH1A1 P00352 6/20 0.36
HSD17B10 Q99714 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
HPGD P15428 2/20 0.36
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 4/20 0.34
PKM P14618 3/20 0.34
MAPT P10636 2/20 0.34
TSHR P16473 2/20 0.33
KMT2A Q03164 1/20 0.33
TP53 P04637 1/20 0.33
RCE1 Q9Y256 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14582767 0.89 NPSR1 (0.59) NPSR1KDM4CKDM4ESTAT3HIF1A
SCHEMBL9633867 0.82 THRB (0.48) THRBRAB9AKDM4EALDH1A1HSD17B10
SCHEMBL4115514 0.79 KDM4E (0.49) NPSR1KDM4CKDM4ESTAT3HIF1A
SCHEMBL9296458 0.75 NPSR1 (0.48) NPSR1KDM4CKDM4ESTAT3HIF1A
SCHEMBL18990911 0.75 NPSR1 (0.48) NPSR1KDM4CKDM4ESTAT3HIF1A
SCHEMBL23925923 0.73 THRB (0.43) THRBRAB9AKDM4EALDH1A1HSD17B10
SCHEMBL28206817 0.71
SCHEMBL22886624 0.69 KDM4E (0.43) NPSR1RAB9AKDM4ESTAT3HIF1A
SCHEMBL20028494 0.67 SMN1; SMN2 (0.58) RAB9AKDM4ESTAT3HIF1AALDH1A1
SCHEMBL23925728 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380347-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-12-01 US disclosed
WO-2021212039-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380347-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL NPSR1 4319/4885THRB 4657/4885RAB9A 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.